{"entity":{"id":"mm014","kind":"drug","name":"MM014","aka":[],"tldr":"MM014 is an in vivo CAR-T programme from Mucommune for solid tumours, in early laboratory development.","summary":"MM014 is listed on the pipeline page of Mucommune as an in vivo CAR-T programme for solid tumours, under its in vivo cell engineering platform. The company does not state the target or the stage on that page, and no clinical trial is registered.","status":"preclinical","asOf":"2026-11-04","links":[{"label":"Mucommune pipeline","url":"https://www.mucommune.com/pipeline"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":["in-vivo-car-t"],"targets":[],"drugs":[],"companies":["mucommune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"MM014","modality":"In vivo CAR-T cell therapy","mechanism":"Described by the company as in vivo CAR-T for solid tumours: the patient's T cells are engineered inside the body rather than in a manufacturing facility.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mm014/","neighbours":{"technology":[{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"}],"company":[{"id":"mucommune","kind":"company","name":"Mucommune","route":"/companies/mucommune/"}]}}